These audio clips feature funded scientists describing research goals as part of the Discovering New Therapeutic Uses for Existing Molecules program.
Clip |
Description |
Preview |
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) Alan Breier, M.D., Indiana University, Indianapolis |
For this project, the research team will test a drug candidate that mimics estrogen’s action in the body — but without its negative side effects — to see if it is safe and relieves symptoms in patients with schizophrenia. |
|
Medication Development of a Novel Therapeutic for Smoking Cessation Darlene H. Brunzell, Ph.D., Virginia Commonwealth University, Richmond |
For this project, the team of researchers will conduct studies in rodents followed by clinical trials with cigarette smokers to test an existing compound as a potential treatment for tobacco cessation. |
|
A Novel Compound for Alcoholism Treatment: A Translational Strategy Lorenzo Leggio, M.D., Ph.D., M.Sc. (NIAAA/NIDA), partner with the University of Rhode Island, Kingston |
For this project, the research team will test an oral medication that blocks a hormone called ghrelin to see if the drug is safe and if it reduces alcohol dependence. |
|
Reuse of ZD4054 for Patients with Symptomatic Peripheral Artery Disease Brian H. Annex, M.D., University of Virginia, Charlottesville |
For this project, researchers will test an investigational drug for its ability to improve blood flow in the legs of patients with peripheral artery disease, which can cause severe leg pain. This drug may relieve this pain, help patients walk further and longer, and reduce the costs of hospitalization and treatment. |
|
Therapeutic Strategy for LAM N. Tony Eissa, M.D., Baylor College of Medicine, Houston |
For this project, the research team aims to determine if blocking Src kinase activity using an investigational drug is safe and can reduce the growth and spread of lymphangioleiomyomatosis (LAM), a progressive lung disease. |
|
Therapeutic Strategy to Slow Progression of Calcific Aortic Valve Stenosis Jordan D. Miller, Ph.D., Mayo Clinic, Rochester, Minnesota |
For this project, the researchers will test the safety of an investigational drug in heart valve disease patients in slowing progression of stenosis, an abnormal narrowing of vessels or other structures. |
|
Translational Neuroscience Optimization of GlyT1 Inhibitor John H. Krystal, M.D., Yale University, New Haven, Connecticut |
For this project, the researchers will use brain imaging studies to determine the safest dose of an experimental drug in healthy subjects and, ultimately, whether it is effective in combination with mind exercises to treat cognitive deficits in schizophrenia patients. |